Seeking to support data management skills development among early- to mid-career malaria researchers, WWARN will host a free practical workshop in April at the Multilateral Initiative on Malaria (MIM) 2018 meeting in Dakar, Senegal.

Resistance to the commonly used antimalarial treatment artesunate might have contributed to the death of a patient suffering from severe malaria on the Thailand-Myanmar border, a recently published article reveals.

A systematic review of research on treatments for malaria in pregnancy has suggested new approaches to analysing available efficacy data and to assessing and reporting safety in studies, two recently published articles report.

Looking forward to the day when all infectious disease data is collected and stored in a common format, WWARN data managers recently completed training provided by the Clinical Data Interchange Standards Consortium (CDISC), which will help advance plans for a more integrated approach.

Citing a rise in global malaria cases last year, World Health Organization officials have released the 2017 World Malaria Report with warnings of stalled progress in the fight against the disease and calls for urgent action to shore up gains made in recent years.

Two new WHO publications highlight the prevalence and impact of substandard and falsified medical products. An estimated 1 in 10 medical products circulating in low- and middle-income countries is either substandard or falsified, according to new research from the World Health Organization (WHO).

New literature review on soil-transmitted helminths provides compelling evidence for the need to develop a data sharing platform to monitor and improve treatment outcomes for this neglected tropical disease.

The IDDO team will be attending this year’s American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting held in Baltimore, USA. Visit the Centre for Tropical Medicine & Global Health booth (number 312) in the exhibition area to meet staff members.

New study explores the current and the historical statistical methods used to better define the efficacy of antimalarials.

Responding to the growing mandate for researchers to share their clinical data, WWARN is joining with partners to host a 4-day workshop in January sponsored by the British Council’s Newton Researcher Links Programme in order to develop the skills and network needed to produce high quality data capab...

The IDDO and Be-cause health Medicine Quality teams will be addressing the issue of poor quality medicines at the forthcoming European Congress on Tropical Medicine and International Health (ECTMIH) in Antwerp, Belgium.

A recently published study credits WWARN for its ‘pioneering’ data sharing achievements which include proving the success of a collaborative data platform as a tool for researchers to conduct individual patient data meta-analyses of malaria clinical studies which inform treatment policy.

Seeking to support data management skills development among early- to mid-career malaria researchers, WWARN will host free workshops at major malaria conferences in the coming year, including MIM.

Over the next few months, the WWARN and IDDO team will be busy travelling to international conferences. We hope to see you there!

The WWARN Informatics team has made the source code behind their online tools, such as online mapping software, freely available. Find out how you can use it.

A new study shows that a dominant multidrug-resistant strain of falciparum malaria poses a serious threat to malaria control and eradication efforts.

The WorldWide Antimalarial Resistance Network (WWARN) has been shortlisted for a 2017 Times Higher Education (THE) Award in the ‘International Collaboration of the Year’ category.

Combining patient data from visceral leishmaniasis (VL) clinical trials would give scientists and clinicians more tools to understand and treat the disease which can be fatal if untreated.

The WorldWide Antimalarial Resistance Network (WWARN) has been shortlisted for a 2017 Times Higher Education (THE) Award in the ‘International Collaboration of the Year’ category.

Dihydroartemisinin-piperaquine (DP), a widely used and effective treatment for falciparum malaria, is safe and unlikely to cause severe drug-induced heart problems, a recently published study has found.